Tim Clackson, Ph.D. is President, and EVP of R&D, of Xilio Therapeutics Inc, a privately held oncology company developing tumor-selective immunotherapies. Prior to Xilio, Tim was President of R&D and Chief Scientific Officer at ARIAD Pharmaceuticals, a global, commercial oncology company acquired by Takeda in 2017. During Tim’s 22-year tenure at ARIAD, he led the multi-disciplinary R&D team that internally discovered and developed five product candidates, including ICLUSIG (ponatinib), approved for the treatment of resistant CML/Ph+ALL, and ALUNBRIG (brigatinib), approved for ALK+ NSCLC. Earlier in his career, Tim was a postdoctoral fellow with Dr. James A. Wells at Genentech, where his studies on growth hormone receptor defined the now-established “hot spot” paradigm for how proteins interact. Tim received his Ph.D. in Biology from Cambridge University for research conducted under Dr. Greg Winter at the MRC Laboratory of Molecular Biology into antibody engineering and the development of antibody phage display technology, subsequently commercialized by Cambridge Antibody Technology. He received his B.A. degree in Biochemistry from Oxford University. Tim serves a member of the boards of directors of Forma Therapeutics, Spring Bank Pharmaceuticals, and the Massachusetts Biotechnology Council (MassBio).